About Hummsa Biotech
Hummsa Biotech is a company based in Kolkata (India) founded in 2022 by Swapnil Sinha and Harshad Lalwani. Hummsa Biotech has raised $166.27 thousand across 2 funding rounds from investors including IIIT Hyderabad, 100X.VC and Yagnesh Sanghrajka. The company has 1 employees as of April 09, 2024. Hummsa Biotech offers products and services including InsGen Kit and Novel Platform Reagent Technology. Hummsa Biotech operates in a competitive market with competitors including PierianDx, Treos Bio, Ignyta, Circular Genomics and Ulisse BioMed, among others.
- Headquarter Kolkata, India
- Employees 1 as on 09 Apr, 2024
- Founders Swapnil Sinha, Harshad Lalwani
- Stage Minicorn
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Hummsa Biotech Private Limited
- Date of Incorporation 26 Apr, 2022
- Jurisdiction Kolkata, West Bengal, India
-
Annual Revenue
$360.71 (USD)0as on Mar 31, 2023
-
Net Profit
-$14.56 K (USD)0as on Mar 31, 2023
-
EBITDA
-$14.56 K (USD)0as on Mar 31, 2023
-
Total Equity Funding
$166.27 K (USD)
in 2 rounds
-
Latest Funding Round
$166.27 K (USD), Seed
Feb 15, 2024
-
Investors
IIIT Hyderabad
& 4 more
-
Employee Count
1
as on Apr 09, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Hummsa Biotech
Hummsa Biotech offers a comprehensive portfolio of products and services, including InsGen Kit and Novel Platform Reagent Technology.
Rapid DNA/RNA sensor for accurate target detection and quantitative results.
Technology for quick, precise detection of critical health targets.
Funding Insights of Hummsa Biotech
Hummsa Biotech has successfully raised a total of $166.27K across 2 strategic funding rounds. The most recent funding activity was a Seed round of $166.27 thousand completed in February 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Hummsa Biotech
Hummsa Biotech has secured backing from 5 investors, including venture fund, angel, and institutional investors. Prominent investors backing the company include IIIT Hyderabad, 100X.VC and Yagnesh Sanghrajka.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage startups are funded by 100X.VC venture capital firm.
|
Locked | Locked | Locked | |
|
Healthcare startups are accelerated by a dedicated incubator program.
|
Locked | Locked | Locked | |
|
Information technology courses are offered at undergraduate and postgraduate levels.
|
Locked | Locked | Locked |
Investor details for Hummsa Biotech
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Hummsa Biotech
Investment portfolio details for Hummsa Biotech
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Hummsa Biotech
Detailed financials for Hummsa Biotech
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Hummsa Biotech Comparisons
Peer comparison for Hummsa Biotech
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Hummsa Biotech
Hummsa Biotech operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as PierianDx, Treos Bio, Ignyta, Circular Genomics and Ulisse BioMed, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Genetic tests for individualized disease diagnosis are provided.
|
|
| Locked | Locked | Locked |
Developer of cancer vaccines and companion diagnostics
|
|
| Locked | Locked | Locked |
Personalized medicine is developed for cancer and autoimmune diseases.
|
|
| Locked | Locked | Locked |
RNA-based diagnostics and therapeutics for depression are developed and provided.
|
|
| Locked | Locked | Locked |
Biological drug monitoring and molecular diagnostics are manufactured.
|
|
| Locked | Locked | Locked |
Developer of a lab on chip microfluidic platform for sequencing and molecular diagnostics using AI
|
Detailed competitors of Hummsa Biotech
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Hummsa Biotech
Complete news archive for Hummsa Biotech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Hummsa Biotech
Hummsa Biotech was founded in 2022 and raised its 1st funding round 1 year after it was founded.
Hummsa Biotech is headquartered in Kolkata, India. It is registered at Kolkata, West Bengal, India.
Harshad Lalwani is the current CEO of Hummsa Biotech. They have also founded this company.
Hummsa Biotech is a funded company, having raised a total of $166.27K across 2 funding rounds to date.
As of Apr 09, 2024, the latest employee count at Hummsa Biotech is 1.
Annual revenue of Hummsa Biotech is $360.71 as on Mar 31, 2023.
Hummsa Biotech was founded in 2022 in Kolkata, India, within the biotechnology sector. A nanotechnology-based device for disease diagnostics is developed by the company, with operations centered on integrating synthetic biology and AI. The product, InsGen, enables simultaneous proprietary assays to address diagnostics for multiple diseases, supporting advancements in healthcare applications across the region.
Hummsa Biotech's top competitors include Circular Genomics, PierianDx and Ignyta.
Hummsa Biotech offers InsGen Kit and Novel Platform Reagent Technology.
Hummsa Biotech has 5 investors. Key investors include IIIT Hyderabad, 100X.VC, Yagnesh Sanghrajka, Shashank Randev, and CIE MedTech Incubator.
The valuation of Hummsa Biotech is $1.01M as of Feb 2024.